We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M Turnover 44.83%
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+30.52%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.74B
AUM Growth
+$261M
Cap. Flow
-$277M
Cap. Flow %
-10.08%
Top 10 Hldgs %
32.74%
Holding
95
New
12
Increased
24
Reduced
31
Closed
21
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$88.4M
2
UTHR icon
United Therapeutics
UTHR
+$54.7M
3
CVS icon
CVS Health
CVS
+$52.7M
4
AVTR icon
Avantor
AVTR
+$43.5M
5
ABBV icon
AbbVie
ABBV
+$41.5M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$60.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$54.5M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$44.3M
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$42.1M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$38.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.29%
2 Miscellaneous 4.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARVN icon
1
Arvinas
ARVN
$468M
$123M 4.48%
2,985,117
+370,157
+14% +$8.65M
2020 Q2
14 quarters
BSX icon
2
Boston Scientific
BSX
$64B
$109M 3.98%
1,890,000
-175,800
-9% -$9.38M
2022 Q1
7 quarters
CI icon
3
CALL
Cigna
CI
$79B
$105M 3.82%
+350,000
New +$102M
2023 Q4
0 quarters
TMO icon
4
Thermo Fisher Scientific
TMO
$258B
$96.9M 3.53%
+182,600
New +$88.4M
2023 Q4
0 quarters
ACHC icon
5
Acadia Healthcare
ACHC
$2.89B
$89.9M 3.28%
1,156,692
+441,692
+62% +$32.7M
2022 Q2
6 quarters
NBIX icon
6
Neurocrine Biosciences
NBIX
$13.9B
$86.7M 3.16%
658,000
+5,900
+0.9% +$679K
2020 Q4
12 quarters
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.22B
$85.4M 3.11%
3,950,000
+1,129,000
+40% +$17.4M
2020 Q2
14 quarters
NTRA icon
8
Natera
NTRA
$58.3B
$69.5M 2.53%
1,110,000
+211,000
+23% +$10.5M
2020 Q3
13 quarters
DHR icon
9
Danaher
DHR
$163B
$67.1M 2.45%
290,000
+90,795
+46% +$19.3M
2023 Q3
1 quarter
THC icon
10
Tenet Healthcare
THC
$22.2B
$65.8M 2.4%
871,000
-92,800
-10% -$5.88M
2022 Q4
4 quarters
KRTX icon
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$65.2M 2.38%
206,000
-80,700
-28% -$15.7M
2022 Q2
6 quarters
FUSN icon
12
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$62.5M 2.28%
6,500,328
+718,478
+12% +$3.49M
2023 Q1
3 quarters
JAZZ icon
13
Jazz Pharmaceuticals
JAZZ
$13.9B
$60.2M 2.19%
489,119
-308,381
-39% -$38.5M
2022 Q2
6 quarters
REGN icon
14
Regeneron Pharmaceuticals
REGN
$82B
$59.7M 2.18%
68,000
+10,000
+17% +$8.23M
2023 Q1
3 quarters
CVS icon
15
CVS Health
CVS
$118B
$58.4M 2.13%
+740,000
New +$52.7M
2023 Q4
0 quarters
BPMC icon
16
DELISTED
Blueprint Medicines
BPMC
$56.7M 2.07%
615,000
-136,600
-18% -$8.85M
2023 Q2
2 quarters
IMGN icon
17
DELISTED
Immunogen Inc
IMGN
$54.2M 1.98%
1,829,215
-88,692
-5% -$1.77M
2023 Q2
2 quarters
IDYA icon
18
IDEAYA Biosciences
IDYA
$3.27B
$54.1M 1.97%
1,520,000
-624,971
-29% -$18.7M
2021 Q1
11 quarters
UTHR icon
19
United Therapeutics
UTHR
$23.2B
$52.2M 1.9%
+237,202
New +$54.7M
2023 Q4
0 quarters
RCKT icon
20
Rocket Pharmaceuticals
RCKT
$259M
$51.5M 1.88%
1,719,103
+131,674
+8% +$2.91M
2022 Q4
4 quarters
ITCI icon
21
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$50.9M 1.85%
710,000
-91,100
-11% -$5.24M
2023 Q3
1 quarter
LLY icon
22
Eli Lilly
LLY
$1.12T
$49.5M 1.81%
85,000
+10,000
+13% +$5.84M
2023 Q2
2 quarters
BHVN icon
23
Biohaven
BHVN
$1.73B
$49.1M 1.79%
1,148,308
-137,092
-11% -$4.26M
2022 Q4
4 quarters
AVTR icon
24
Avantor
AVTR
$10.9B
$48.4M 1.77%
+2,121,844
New +$43.5M
2023 Q4
0 quarters
ZTS icon
25
Zoetis
ZTS
$32.4B
$47.4M 1.73%
240,000
-22,100
-8% -$3.91M
2023 Q1
3 quarters
1
2 3 4

Similar funds

ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return
PWS
Proactive Wealth Strategies Marietta, Georgia $623M AUM 30.7% 1-Year Est. Return
LWP
LMG Wealth Partners Shreveport, Louisiana $626M AUM 36.27% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Avidity Partners Management's Q4 2023 Portfolio in Review

As of Q4 2023, Avidity Partners Management held 95 positions worth $2.74B, up 11% from $2.48B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Avidity Partners Management withdrew a net $277M in Q4 2023, closing 21 positions and reducing 31 holdings. Its most notable exit was Cigna, an estimated $60.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Avidity Partners Management opened a new position in Thermo Fisher Scientific worth $96.9M.

  • Avidity Partners Management's largest Q4 2023 buy was Thermo Fisher Scientific: 182,600 shares worth $96.9M.
  • Avidity Partners Management added most to Structure Therapeutics in Q4 2023, an estimated $33.2M increase.
  • Avidity Partners Management's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $38.5M.
  • Avidity Partners Management fully exited Cigna in Q4 2023, selling an estimated $60.7M.
  • Avidity Partners Management's ten largest holdings make up 33% of its $2.74B portfolio in Q4 2023.
  • Avidity Partners Management opened 12 new positions and closed 21 in Q4 2023.
  • Avidity Partners Management's portfolio value rose 11% quarter-over-quarter to $2.74B.

Based on Avidity Partners Management's 13F filing for Q4 2023, filed 14 Feb 2024.